CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells

American Journal of Pathology

Volumn 172, Issue 2, 2008, Pages 510-520

  Hirsch, Burkhard ^a   Hummel, Michael ^a   Bentink, Stefan ^b   Fouladi, Fariba ^a   Spang, Rainer ^b   Zollinger, Raphael ^a   Stein, Harald ^a   Dürkop, Horst ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL KILLING; CELL PROLIFERATION; DOWN REGULATION; ENZYME ACTIVATION; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; IMMUNOBLOTTING; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REED STERNBERG CELL;

EID: 39549084701     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2008.070858     Document Type: Article

References (40)

1. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G: CD30 in normal and neoplastic cells. Clin Immunol 1999, 90:157-164
2. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, Senter PD: Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003, 21:778-784
3. Wendtner CM, Schmitt B, Gruss HJ, Druker BJ, Emmerich B, Goodwin RG, Hallek M: CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line. Cancer Res 1995, 55:4157-4161
4. Hübinger G, Muller E, Scheffrahn I, Schneider C, Hildt E, Singer BB, Sigg I, Graf J, Bergmann L: CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene 2001, 20:590-598
5. Levi E, Pfeifer WM, Kadin ME: CD30-activation-mediated growth inhibition of anaplastic large-cell lymphoma cell lines: apoptosis or cell-cycle arrest? Blood 2001, 98:1630-1632
6. Mir SS, Richter BW, Duckett CS: Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin's disease cells. Blood 2000, 96:4307-4312
7. Nishikori M, Ohno H, Haga H, Uchiyama T: Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-kappaB p52, which is associated with hyperphosphorylated Bcl-3. Cancer Sci 2005, 96:487-497
8. Staber PB, Noehammer C, Durkop H, Schauer S, Kenner L, Linkesch W, Hoefler G: mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma. Leuk Res 2006, 30:343-348
9. Wajant H, Grell M, Scheurich P: TNF receptor associated factors in cytokine signaling. Cytokine Growth Factor Rev 1999, 10:15-26
10. Kucharczak J, Simmons MJ, Fan Y, Gelinas C: To be, or not to be: nF-kappaB is the answer. Role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003, 22:8961-8982
11. Bonizzi G, Karin M: The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004, 25:280-288
12. Hinz M, Loser P, Mathas S, Krappmann D, Dorken B, Scheidereit C: Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin's/Reed-Sternberg cells. Blood 2001, 97:2798-2807
13. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C: Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin's/Reed-Sternberg cells. Oncogene 1999, 18:943-953
14. Dürkop H, Hirsch B, Hahn C, Foss HD, Stein H: Differential expression and function of A20 and TRAF1 in Hodgkin's lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation. J Pathol 2003, 200:229-239
15. Dürkop H, Hirsch B, Hahn C, Stein H: cIAP2 is highly expressed in Hodgkin's-Reed-Sternberg cells and inhibits apoptosis by interfering with constitutively active caspase-3. J Mol Med 2006, 84:132-141
16. Mathas S, Lietz A, Anagnostopoulos I, Hummel F, Wiesner B, Janz M, Jundt F, Hirsch B, Johrens-Leder K, Vornlocher HP, Bommert K, Stein H, Dorken B: c-FLIP mediates resistance of Hodgkin's/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004, 199:1041-1052
17. Wood KM, Roff M, Hay RT: Defective IkappaBalpha in Hodgkin's cell lines with constitutively active NF-kappaB. Oncogene 1998, 16:2131-2139
18. Seitz V, Hummel M, Anagnostopoulos I, Stein H: Analysis of BCL-6 mutations in classic Hodgkin's disease of the B- and T-cell type. Blood 2001, 97:2401-2405
19. Re D, Kuppers R, Diehl V: Molecular pathogenesis of Hodgkin's lymphoma. J Clin Oncol 2005, 23:6379-6386
20. Jung W, Krueger S, Renner C, Gause A, Sahin U, Trumper L, Pfreundschuh M: Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources. Mol Immunol 1994, 31:1329-1334
21. Schreiber E, Matthias P, Muller MM, Schaffner W: Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 1989, 17:6419
22. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984, 32:219-229
23. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408
24. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M: Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002, 18(Suppl 1):S96-S104
25. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264
26. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116-5121
27. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C, Dorken B: Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997, 100:2961-2969
28. Horie R, Watanabe T, Morishita Y, Ito K, Ishida T, Kanegae Y, Saito I, Higashihara M, Mori S, Kadin ME, Watanabe T: Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin's-Reed-Sternberg cells. Oncogene 2002, 21:2493-2503
29. Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866
30. Wright CW, Rumble JM, Duckett CS: CD30 activates both the canonical and alternative NF-kappa B pathways in anaplastic large cell lymphoma cells. J Biol Chem 2007, 282:10252-10262
31. Djavaheri-Mergny M, Javelaud D, Wietzerbin J, Besancon F: NF-kappaB activation prevents apoptotic oxidative stress via an increase of both thioredoxin and MnSOD levels in TNFalpha-treated Ewing sarcoma cells. FEBS Lett 2004, 578:111-115
32. Hübinger G, Schneider C, Stohr D, Ruff H, Kirchner D, Schwanen C, Schmid M, Bergmann L, Muller E: CD30-induced up-regulation of the inhibitor of apoptosis genes cIAP1 and cIAP2 in anaplastic large cell lymphoma cells. Exp Hematol 2004, 32:382-389
33. Böll B, Hansen H, Heuck F, Reiners K, Borchmann P, Rothe A, Engert A, Pogge von SE: The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood 2005, 106:1839-1842
34. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, Keler T, Graziano R, Blanset D, Yellin M, Fischkoff S, Assad A, Borchmann P: Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007, 25:2764-2769
35. Nonaka M, Horie R, Itoh K, Watanabe T, Yamamoto N, Yamaoka S: Aberrant NF-kappaB2/p52 expression in Hodgkin's/Reed-Sternberg cells and CD30-transformed rat fibroblasts. Oncogene 2005, 24:3976-3986
36. García JF, Camacho FI, Morente M, Fraga M, Montalban C, Alvaro T, Bellas C, Castano A, Diez A, Flores T, Martin C, Martinez MA, Mazorra F, Menarguez J, Mestre MJ, Mollejo M, Saez AI, Sanchez L, Piris MA: Hodgkin's and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003, 101:681-689
37. Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F, Bommert K, Mechta-Grigoriou F, Stein H, Dorken B, Scheidereit C: Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin's lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 2002, 21:4104-4113
38. Janz M, Hummel M, Truss M, Wollert-Wulf B, Mathas S, Johrens K, Hagemeier C, Bommert K, Stein H, Dorken B, Bargou RC: Classical Hodgkin's lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin's/Reed-Sternberg cells. Blood 2006, 107:2536-2539
39. Horie R, Watanabe M, Ishida T, Koiwa T, Aizawa S, Itoh K, Higashihara M, Kadin ME, Watanabe T: The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma. Cancer Cell 2004, 5:353-364
40. Hsu FY, Johnston PB, Burke KA, Zhao Y: The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner. Cancer Res 2006, 66:9002-9008